Physician profile
Lane Miller
NPI 1316986631
$11,113.57
in general payments reported to CMS, 2019-2025
47 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,658 · 2020: $969 · 2021: $1,849 · 2022: $1,645 · 2023: $1,829 · 2024: $1,830 · 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,993.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,951.82 | 2019-2025 | Aveir, Ensite, Jot Dx |
| E.R. Squibb & Sons, L.L.C. | $935.77 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $934.67 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $849.74 | 2019-2025 | |
| Endologix LLC | $688.74 | 2020-2023 | |
| Pfizer INC. | $538.80 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $299.55 | 2019-2024 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $237.21 | 2022-2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $227.89 | 2019-2021 | |
| Esperion Therapeutics, INC. | $226.70 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $225.46 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $225.26 | 2021-2025 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $215.27 | 2019-2024 | Farxiga |
| Cardinal Health 200 LLC | $181.36 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $168.02 | 2019-2022 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $165.30 | 2024 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.85 | 2019-2025 | Jardiance |
| Biotronik INC. | $157.59 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $132.82 | 2021-2024 | Verquvo |
| Daiichi Sankyo INC. | $128.99 | 2023-2024 | Injectafer |
| Amarin Pharma, INC. | $124.99 | 2019 | |
| Novo Nordisk INC | $114.03 | 2019-2025 | Rybelsus, Ozempic |
| Angiodynamics, INC. | $104.06 | 2023-2024 | Auryon Laser System 100-120 Vac |
| Boston Scientific Corporation | $99.15 | 2019-2025 | Bodyguardian, Watchman Flx |
| Regeneron Healthcare Solutions, INC. | $94.19 | 2019 | |
| Chiesi USA, INC. | $78.08 | 2022-2023 | Kengreal |
| Kowa Pharmaceuticals America, INC. | $77.97 | 2020-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $64.23 | 2024 | Arcalyst |
| Terumo Medical Corporation | $62.72 | 2020-2021 | |
| W. L. Gore & Associates, INC. | $56.09 | 2024 | Gore Excluder Aaa Endoprosthesis |
| Kiniksa Pharmaceuticals, LTD. | $54.14 | 2021-2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $53.29 | 2023-2024 | Inpefa |
| Arbor Pharmaceuticals, INC. | $51.14 | 2019-2021 | |
| Abiomed | $49.81 | 2019-2024 | Impella |
| Philips North America LLC | $47.11 | 2022 | |
| Cardiovascular Systems INC. | $45.25 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $38.11 | 2024 | Assure Wcd |
| Agepha Pharma Fz LLC | $34.23 | 2025 | Lodoco |
| Cordis US Corp. | $33.30 | 2022-2025 | Angioguard |
| Scpharmaceuticals INC. | $32.10 | 2023 | |
| Inari Medical, INC. | $29.54 | 2021 | |
| Medtronic, INC. | $22.98 | 2021 | |
| Atricure, INC. | $21.90 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Cardiva Medical, INC. | $21.24 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Cvrx, INC. | $19.82 | 2024 | Barostim Neo System |
| Lundbeck LLC | $18.10 | 2019 | |
| Shockwave Medical, INC | $17.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lane Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.